CD 27 and CD 81 in Multiple Myeloma: Correlation with Clinicopathological Features and Response to Therapy | ||
| Egyptian Reviews for Medical and Health Sciences | ||
| Article 1, Volume 7, Issue 1, December 2025, Pages 1-22 PDF (804.7 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ermhs.2025.432586.1076 | ||
| Authors | ||
| Tasneem M. Fenoun* ; F.E.I. Ghabrial; El Menshawy N.; Ghazy H.F | ||
| Medical Oncology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt | ||
| Abstract | ||
| Multiple Myeloma (MM) is a neoplastic plasma cell (PC) disorder, characterized by clonal proliferation of malignant PCs in the bone marrow (BM) and is accompanied by increased level of monoclonal protein in the blood and/or urine. Myeloma PCs demonstrate phenotypes which deviate from those typically seen in normal BM PCs. Multiparametric flow cytometry (MFC) is a method that enables the characterization of malignant PCs immunophenotype. CD27 and CD81 are PC surface markers implicated in MM biology. Their prognostic and predictive value remains unclear. This study aimed to assess correlation between the expression of CD27 and CD81 on BM samples of adult Egyptian MM cases by flow cytometry, and different clinico-pathological features, and its impact on response to treatment. This retrospective-descriptive analytical study included 90 MM patients diagnosed at the Oncology Center, Mansoura University, between May 2018 and October 2024. MFC was used to assess CD27 and CD81 expression. Associations with clinicopathological features, response to treatment, disease-free survival (DFS), and overall survival (OS) were analyzed. CD27 negative expression correlated with elevated LDH levels. Leucopenia showed numerical but no statistical significance. CD81 negative and weak positive expression correlated with elevated LDH levels. No statistical significant difference was detected in response to treatment, relapse incidence, DFS and OS in correlation with CD27 and CD81 expression. It can be concluded that CD27 and CD81 are valuable immunophenotypic markers in MM with well-characterized biological functions. In this study, CD27 negativity was associated with elevated LDH levels and inferior early treatment response but did not predict long-term survival outcomes. CD81 expression did not demonstrate significant prognostic or predictive associations. | ||
| Keywords | ||
| Multiple Myeloma; CD27; CD81; Immuno-phenotype; Prognostic markers; Clinicopathological features; Treatment response | ||
|
Statistics Article View: 14 PDF Download: 3 |
||
